Neurocrine (NBIX) Stock Forecast & Price Target

Compare

1,453 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NBIX Analyst Ratings

Strong Buy

21 Buy

3 Hold

0 Sell

Based on 24 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$166.74

▲(23.12% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $166.74 with a high forecast of $200.00 and a low forecast of $124.00. The average price target represents a 23.12% change from the last price of $135.43.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","129":"$129","153":"$153","177":"$177","201":"$201"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":166.74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$166.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$124.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,129,153,177,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.91,134.37846153846152,139.84692307692308,145.3153846153846,150.78384615384616,156.25230769230768,161.72076923076924,167.18923076923076,172.65769230769232,178.12615384615384,183.5946153846154,189.06307692307692,194.53153846153845,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.91,131.82,134.73,137.64,140.55,143.46,146.37,149.28,152.19,155.1,158.01,160.92000000000002,163.83,{"y":166.74,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.91,128.53230769230768,128.15461538461537,127.77692307692307,127.39923076923077,127.02153846153846,126.64384615384616,126.26615384615384,125.88846153846154,125.51076923076923,125.13307692307693,124.75538461538461,124.37769230769231,{"y":124,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":153.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.89,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$200.00

Average Price Target$166.74

Lowest Price Target$124.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Bryce Generon

TR | OpenAI - 4o

$145→$152

Buy

12.24%

Upside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

Sumant Kulkarni

Canaccord Genuity

$160

Buy

18.14%

Upside

Reiterated

08/14/25

Neurocrine's Strong Market Performance and Promising Pipeline Justify Buy RatingWe recently hosted a fireside chat with NBIX's CEO at our 2025 Boston, MA. Recall NBIX has two products on the market currently, i.e., Ingrezza (valbenazine for tardive dyskinesia/TD, Huntington's chorea) and Crenessity (crinecerfont for classic congenital adrenal hyperplasia/cCAH). The company also has a robust pipeline, which it plans to showcase at an R&D Day on 12/16.

Evan Seigerman

BMO Capital

$124

Hold

-8.44%

Downside

Reiterated

08/04/25

Neurocrine (NBIX) Gets a Hold from BMO Capital

Cory Kasimov

Evercore ISI

$190→$200

Buy

47.68%

Upside

Reiterated

07/31/25

Evercore ISI Sticks to Their Buy Rating for Neurocrine (NBIX)

Andrew Fein

H.C. Wainwright

$168

Buy

24.05%

Upside

Reiterated

07/31/25

Buy Rating for Neurocrine's Crenessity Driven by Strong Sales and Transformative Impact on CAH Treatment

Myles Minter

William Blair

―

Buy

―

Reiterated

07/31/25

Positive Outlook for Neurocrine: Strong Performance and Growth Potential Drive Buy RatingWe see potential investor concern surrounding Ingrezza’s sales outlook, particularly given its narrowing of 2025 sales guidance below its original upper-bound set earlier this year (see below). This is largely due to declining net price assumptions with heavier Part D contracting, but the upside here is that volume has increased with record number patient new starts on therapy being reported. Thus, the debate will now become if increased volumes, particularly in 2026, can overcome pricing pressures as Ingrezza looks to compete against Austedo, currently under the CMS Part D price negotiation procedure within the IRA. Crenessity revenue for the second quarter of $53.2 million significantly beat our estimate of $16.8 million as well as the consensus estimate of $24.0 million.

Marc Goodman

Leerink Partners

$160

Buy

18.14%

Upside

Reiterated

07/31/25

Neurocrine's Promising Financial Outlook: Strong Crenessity Performance and Strategic Ingrezza Adjustments Drive Buy Rating

Yatin Suneja

Guggenheim

$165→$175

Buy

29.22%

Upside

Reiterated

07/31/25

Guggenheim Reaffirms Their Buy Rating on Neurocrine (NBIX)Guggenheim analyst Yatin Suneja raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $175.00 (from $165.00) while maintaining a Buy rating.

Ami Fadia

Needham

$139→$161

Buy

18.88%

Upside

Reiterated

07/31/25

Neurocrine's Strong Financial Performance and Growth Prospects Drive Buy Rating

Danielle Brill

Truist Financial

$163→$165

Buy

21.83%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)

Laura Chico

Wedbush

$137→$141

Buy

4.11%

Upside

Reiterated

07/31/25

Neurocrine price target raised to $141 from $137 at WedbushNeurocrine price target raised to $141 from $137 at Wedbush

Paul Matteis

Stifel Nicolaus

$166→$174

Buy

28.48%

Upside

Reiterated

07/31/25

Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), GE Healthcare Technologies Inc (GEHC)

Phil Nadeau

TD Cowen

$165→$170

Buy

25.53%

Upside

Reiterated

07/31/25

Neurocrine's Strong Growth Potential and Positive Outlook Justify Buy Rating

Sean Laaman

Morgan Stanley

$150→$158

Buy

16.67%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: Align Tech (NASDAQ: ALGN) and Neurocrine (NASDAQ: NBIX)

Jay Olson

Oppenheimer

$192

Buy

41.77%

Upside

Reiterated

07/31/25

Oppenheimer Sticks to Its Buy Rating for Neurocrine (NBIX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Bryce Generon

TR | OpenAI - 4o

$145→$152

Buy

12.24%

Upside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

Sumant Kulkarni

Canaccord Genuity

$160

Buy

18.14%

Upside

Reiterated

08/14/25

Evan Seigerman

BMO Capital

$124

Hold

-8.44%

Downside

Reiterated

08/04/25

Neurocrine (NBIX) Gets a Hold from BMO Capital

Cory Kasimov

Evercore ISI

$190→$200

Buy

47.68%

Upside

Reiterated

07/31/25

Evercore ISI Sticks to Their Buy Rating for Neurocrine (NBIX)

Andrew Fein

H.C. Wainwright

$168

Buy

24.05%

Upside

Reiterated

07/31/25

Buy Rating for Neurocrine's Crenessity Driven by Strong Sales and Transformative Impact on CAH Treatment

Myles Minter

William Blair

―

Buy

―

Reiterated

07/31/25

Marc Goodman

Leerink Partners

$160

Buy

18.14%

Upside

Reiterated

07/31/25

Neurocrine's Promising Financial Outlook: Strong Crenessity Performance and Strategic Ingrezza Adjustments Drive Buy Rating

Yatin Suneja

Guggenheim

$165→$175

Buy

29.22%

Upside

Reiterated

07/31/25

Ami Fadia

Needham

$139→$161

Buy

18.88%

Upside

Reiterated

07/31/25

Neurocrine's Strong Financial Performance and Growth Prospects Drive Buy Rating

Danielle Brill

Truist Financial

$163→$165

Buy

21.83%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)

Laura Chico

Wedbush

$137→$141

Buy

4.11%

Upside

Reiterated

07/31/25

Neurocrine price target raised to $141 from $137 at WedbushNeurocrine price target raised to $141 from $137 at Wedbush

Paul Matteis

Stifel Nicolaus

$166→$174

Buy

28.48%

Upside

Reiterated

07/31/25

Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), GE Healthcare Technologies Inc (GEHC)

Phil Nadeau

TD Cowen

$165→$170

Buy

25.53%

Upside

Reiterated

07/31/25

Neurocrine's Strong Growth Potential and Positive Outlook Justify Buy Rating

Sean Laaman

Morgan Stanley

$150→$158

Buy

16.67%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: Align Tech (NASDAQ: ALGN) and Neurocrine (NASDAQ: NBIX)

Jay Olson

Oppenheimer

$192

Buy

41.77%

Upside

Reiterated

07/31/25

Oppenheimer Sticks to Its Buy Rating for Neurocrine (NBIX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

1 Month

xxx

Success Rate

15/24 ratings generated profit

Average Return

+0.76%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +0.76% per trade.

3 Months

xxx

Success Rate

18/28 ratings generated profit

Average Return

+3.75%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +3.75% per trade.

1 Year

Phil NadeauTD Cowen

Success Rate

16/22 ratings generated profit

Average Return

+8.44%

reiterated a buy rating 24 days ago

Copying Phil Nadeau's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +8.44% per trade.

2 Years

xxx

Success Rate

22/28 ratings generated profit

Average Return

+14.19%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +14.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NBIX has received 43 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 166.74.

Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $1.58 with a range of $1.14 to $2.12. The previous quarter’s EPS was $1.06. NBIX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.04% of the time in the same period. In the last calendar year NBIX has Outperformed its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $745.41M with a range of $709.40M to $788.24M. The previous quarter’s sales results were $687.50M. NBIX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.88% of the time in the same period. In the last calendar year NBIX has Outperformed its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 166.74.

What is NBIX’s upside potential, based on the analysts’ average price target?

Neurocrine has 23.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NBIX a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy which is based on 21 buy ratings, 3 hold ratings and 0 sell ratings.

What is Neurocrine’s price target?

The average price target for Neurocrine is 166.74. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $124.00. The average price target represents 23.12% Increase from the current price of $135.43.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of NBIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Neurocrine (NBIX) Stock Forecast & Price Target

NBIX Analyst Ratings

NBIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NBIX Analyst Recommendation Trends

NBIX Financial Forecast

NBIX Earnings Forecast

NBIX Sales Forecast

NBIX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts